An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

This editorial originally ran in fellow CNHI paper The (Sunbury). Individuals have long valued privacy for themselves and their families, while often — knowingly or unknowingly — giving it away. It is ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

The global Retinal Vein Occlusion (RVO) treatment market was valued at approximately USD 2.65 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6.92% over the ...

Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

BACKGROUND: Vascular aging is an important phenotype characterized by structural and geometric remodeling. Some individuals ...